Ocumension Therapeutics (SEHK:1477) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

1477 Aktienübersicht

Ocumension Therapeutics ist zusammen mit seinen Tochtergesellschaften als pharmazeutisches Plattformunternehmen für Augenheilkunde in der Volksrepublik China tätig.

Über das Unternehmen

1477 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 93.7% pro Jahr

Die Erträge sind in den letzten 5 Jahren um 36.4% pro Jahr gestiegen.

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für 1477 festgestellt.

Ocumension Therapeutics Wettbewerber

YiChang HEC ChangJiang Pharmaceutical

SEHK:1558

HK$8.3b

Consun Pharmaceutical Group

SEHK:1681

HK$5.3b

China Shineway Pharmaceutical Group

SEHK:2877

HK$6.2b

Tong Ren Tang Technologies

SEHK:1666

HK$7.1b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Ocumension Therapeutics
Historical stock prices
Current Share Price	HK$6.77
52 Week High	HK$10.40
52 Week Low	HK$4.51
Beta	0.82
1 Month Change	-5.58%
3 Month Change	31.71%
1 Year Change	-4.92%
3 Year Change	-77.58%
5 Year Change	n/a
Change since IPO	-81.70%

Aktuelle Nachrichten und Updates

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Recent updates

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23

Aktionärsrenditen

	1477	HK Pharmaceuticals	HK Markt
7D	-0.1%	4.0%	1.1%
1Y	-4.9%	-3.8%	-0.5%

Rendite im Vergleich zur Industrie: 1477 unter dem Niveau der Branche Hong Kong Pharmaceuticals, die im vergangenen Jahr eine Rendite von -3.2% erzielte.

Rendite vs. Markt: 1477 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 1 erzielte.

Preisvolatilität

Is 1477's price volatile compared to industry and market?
1477 volatility
1477 Average Weekly Movement	6.0%
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	7.3%
10% most volatile stocks in HK Market	15.7%
10% least volatile stocks in HK Market	3.7%

Stabiler Aktienkurs: 1477Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: 1477Die wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2017	444	Victor Liu	www.ocumension.com

Ocumension Therapeutics ist zusammen mit seinen Tochtergesellschaften als pharmazeutisches Plattformunternehmen für Augenheilkunde in der Volksrepublik China tätig. Das Unternehmen erforscht, entwickelt und vermarktet Therapien für Augenpatienten. Sein Portfolio umfasst Produkte und Medikamente zur Behandlung von chronischer, nicht-infektiöser Uveitis, Blepharitis, infektiöser und allergischer Konjunktivitis, diabetischem Makulaödem, trockenem Auge, Glaukom und okulärem Bluthochdruck, postoperativen Entzündungen, choroidaler Neovaskularisation, bakterieller Konjunktivitis, Retinitis pigmentosa, akutem Glaukom, altersbedingter Makuladegeneration, Abstoßung von Hornhauttransplantaten, Myopie und optischer Neuritis.

Ocumension Therapeutics's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Ocumension Therapeutics im Vergleich zum Marktanteil des Unternehmens?
1477 grundlegende Statistiken
Marktanteil	HK$4.70b
Gewinn(TTM)	-HK$409.47m
Umsatz(TTM)	HK$265.62m

17.7x

Kurs-Umsatz-Verhältnis

-11.5x

Kurs-Gewinn-Verhältnis

Ist 1477 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
1477 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥246.37m
Kosten der Einnahmen	CN¥102.00m
Bruttogewinn	CN¥144.37m
Sonstige Ausgaben	CN¥524.15m
Umsatz	-CN¥379.79m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.55
Bruttomarge	58.60%
Nettogewinnspanne	-154.16%
Schulden/Eigenkapital-Verhältnis	4.1%

Wie hat sich 1477 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

1477 Aktienübersicht

Belohnungen

Risikoanalyse

Ocumension Therapeutics Wettbewerber

SEHK:1558

HK$8.3b

SEHK:1681

HK$5.3b

SEHK:2877

HK$6.2b

SEHK:1666

HK$7.1b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Recent updates

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Consensus forecasts updated

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Consensus forecasts updated

Forecast to breakeven in 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China

Consensus forecasts updated

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Erträge & Einnahmen